What’s Ahead for WEED INCORPORATED (OTCMKTS:BUDZ) After Less Shorted Shares?

September 17, 2017 - By Peter Erickson

The stock of WEED INCORPORATED (OTCMKTS:BUDZ) registered a decrease of 13.6% in short interest. BUDZ’s total short interest was 73,700 shares in September as published by FINRA. Its down 13.6% from 85,300 shares, reported previously. With 73,200 shares average volume, it will take short sellers 1 days to cover their BUDZ’s short positions.

The stock increased 2.47% or $0.024 on September 15, reaching $0.994. About 37,867 shares traded or 13.21% up from the average. Weed Inc (OTCMKTS:BUDZ) has 0.00% since September 17, 2016 and is . It has underperformed by 16.70% the S&P500.

WEED, Inc. is focused on purchasing land and building commercial grade Cultivation Centers to consult, assist, manage and lease to licensed dispensary owners and organic grow operators on a contract basis, with a concentration on the legal and medical marijuana sector. The company has market cap of $99.39 million. The Firm intends to become a seed-to-sale firm providing infrastructure, financial solutions and real estate options in the medical marijuana market. It currently has negative earnings. The Firm plans to incorporate approximately eight subsidiaries to focus on various divisions, such as Mining; Marijuana Farms; Security Services; Legal, licensing, consulting and management; Land acquisition; Financial solutions; Wholesale and retail sales, and International operations.

More recent Weed Inc (OTCMKTS:BUDZ) news were published by: Finance.Yahoo.com which released: “WEED, Inc. USA Goes Global: Forms WEED AUSTRALIA LTD. on the Gold Coast” on April 05, 2017. Also Fool.com published the news titled: “What Medical Marijuana, Inc. does” on June 16, 2017. Fool.com‘s news article titled: “This marijuana stock has had a terrible run of late and here’s why” with publication date: September 13, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.